Isomorphic Labs, the AI drug discovery company founded by DeepMind's Demis Hassabis, has raised $2.1 billion in Series B funding led by Thrive Capital. The round includes Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
Isomorphic Labs, the DeepMind spin-off focused on AI-driven drug discovery, has unveiled a new AI that scientists are calling a generational leap comparable to AlphaFold.
Google DeepMind spinoff Isomorphic Labs revealed IsoDDE, an AI drug design engine that more than doubles AlphaFold 3's accuracy. It reduces drug discovery timelines from years to months, transforming pharmaceutical R&D.